Laurus Labs (LAURUSLABS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jul, 2026Opening remarks and agenda
Meeting conducted via audio-visual means, with e-voting and video conferencing provided for shareholder participation.
Statutory registers and AGM documents available electronically; quorum confirmed as per legal requirements.
Chairman introduced board members, auditors, and confirmed the meeting was duly constituted.
Financial performance review
Gross margins exceeded 60%, EBITDA margins around 28%, and net debt/EBITDA at 1.3.
Return on equity and capital employed both healthy at about 17%.
CDMO revenue continued to grow, supporting overall company growth.
Profit for 2026 reached INR 889 crore, up from INR 828 crore in 2022.
Board and executive committee updates
Board included executive and independent directors joining from multiple locations globally.
Two directors were unable to attend due to preoccupations.
Latest events from Laurus Labs
- Record revenue and profit growth, led by CDMO and generics, with margins and EPS surging.LAURUSLABS
Q1 26/27 - FY26 saw 23% revenue and 148% profit growth, with strong CDMO and generics momentum.LAURUSLABSQ4 25/26
- 9M FY26 revenue up 30% and net profit up 388%, led by generics and CDMO growth.LAURUSLABSQ3 25/26
- 33–35% revenue growth, 985% net profit surge, margin expansion, and interim dividend declared.LAURUSLABSQ2 25/26
- Revenue rose 31% to ₹1,570 crore, with net profit and margins sharply higher on CDMO strength.LAURUSLABSQ1 25/26
- Flat revenue, margin pressure, lower profit, but H2 growth and dividend expected.LAURUSLABSQ2 24/25
- Q1 FY25 revenue rose 1% YoY, gross margin hit 55.1%, and a new Independent Director was appointed.LAURUSLABSQ1 24/25
- Strong FY2025 revenue and profit growth, led by CDMO expansion and margin gains, with positive FY2026 outlook.LAURUSLABSQ4 24/25
- Q3 FY25 revenue and profit surged on CDMO and FDF strength, with major investments fueling growth.LAURUSLABSQ3 24/25